Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


June 3, 2013 - Living With Myeloma - Treatment and Side Effects Management

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: June 3, 2013
Time: 12:00 p.m. - 1:30 p.m. ET
Location: Telephone/Web
View: Program Slides 
Read: Myeloma News | Transcript
Listen: Presentation | Q&A Session
Access: Virtual lecture

Topics Covered 

  • Current and emerging therapies for myeloma
  • The role of clinical trials in the advancement of myeloma treatment for patients
  • The importance of patient-provider communications about treatment side effects and management
  • Communication touch points among patients and healthcare providers
  • Issues for people living with myeloma


S. Vincent Rajkumar, MD
Professor of Medicine
, Mayo Clinic Myeloma, Amyloidosis, Dysproteinenemia Group
Mayo Clinic
Rochester, MN

Questions Asked by the Myeloma Community

  • What is the connection between myeloma and amyloidosis?
  • And there difficulties in treating a patient who has myeloma and amyloidosis? What are the treatment options?
  • What has your research shown regarding how long a patient should be on bisphosphonates after stem cell transplant?
  • What can be done about the large red welts at the site of the injection after receiving subcutaneous bortezomib (Velcade®) injections twice a month?
  • What are the crucial questions or things that a newly diagnosed patient needs to ask about or be aware of?
  • After taking Velcade, diarrhea and very severe neuropathy in the toes and the fingers developed. How are these issues cured?
  • What is the longest length of time that a patient can remain on lenalidomide (Revlimid®) after transplant, if the patient has no serious side effects?
  • Other than lab tests, how would you recognize a patient might be refractory to Revlimid?
  • Isn't zoledronic acid (Zometa®) good for your bones to strengthen them?
  • If a patient has no chromosomal or genetic abnormalities, is it possible for this patient to develop such anomalies in the future?
  • What is your opinion on maintenance medication?
  • What can reduce the side effect of significant flushing and burning in the eyes from dexamethasone?
  • Apart from getting filgrastim (Neupogen®), what can be done to help increase the white count?
  • Can you please talk about the evolution of vaccines for the treatment of multiple myeloma, particularly things that are in trial now?
  • Regarding subcutaneous Velcade for maintenance post-transplant after a remission has been achieved, what is the dosage recommended, the frequency recommended, and the length of time that Velcade should be used for maintenance?
  • After initial therapy, if remission is achieved, would you also suggest a stem cell transplant be done?
  • Is there a supplement or supplements that should or shouldn't be taken if a patient has myeloma?
  • Are emotional outbursts a side effect of Velcade?
  • Do you have any thoughts on taking curcumin together with Revlimid for maintenance?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Celgene Corporation, Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals, Inc.

last updated on Tuesday, January 13, 2015